

## ABSTRACT SUBMISSION GUIDELINES

### ICCS

**On-line Abstract Submission Process Begins: November 14, 2016**  
**Abstract Deadline Date: January 10, 2017 @ 11:59 PM GMT**

The submission of an abstract affirms that all authors named in the abstract have agreed to its submission for presentation at the Annual Meeting of the International Children's Continence Society and may be published in the Journal of Pediatric Urology® exactly as submitted.

Submission of an abstract constitutes the author's commitment to present the abstract as accepted. Expenses associated with the preparation, submission and presentation of an abstract are the responsibility of the author/presenter. Submitted abstracts are graded individually by peer reviewers based on scientific merit and originality. Abstracts must be written in English and, if accepted, presented in English.

The ICCS Program Committee will determine the format of the presentation. Accepted abstracts are assigned for presentation at a podium session (either a Long oral or Short oral) or a unmoderated poster session.

Abstract acceptance or rejection will be decided by judging the results as presented in the abstract, not on any presumed additional data accumulated after submission.

Publication of the complete study upon which the abstract is based in a journal or electronic publication before presentation is strictly prohibited and will result in outright rejection of the abstract. Multiple abstracts by the same authors based on the same study population or data will also be rejected outright.

#### *Preparation of Abstracts*

**1. Size:** The size of the abstract is limited to 2,280 characters not including spaces. This includes title, body of abstract, tables and graphics. Tables are calculated at 225 characters per table. Graphics are calculated at 225 characters per graphic.

**2. Title:** The title should clearly define the topic and contain no abbreviations.

**3. Authors:** List the primary author's full name, followed by the other authors' names. Spell out completely the names of all authors using full first name, middle initial and last name. (Maintain consistency in authors' names on multiple abstracts to avoid duplication in the Author Index.)

**4. Presenting Author:** If the author(s) of the abstract is an employee(s) of or has a financial relationship with the commercial interest which controls the content of the presentation then he/she cannot be the presenting author. However, principal investigators responsible for research and development are permitted to present as long as they resolve their COI and as long as they are not employees of the commercial interest. In all printed publications the presenting author will be denoted with an asterisk (\*). Please note: As of April 1, 2017 no changes to the Presenting Author will be made in the Program Abstract Publication.

**5. Body of Abstract:** The abstract should be informative and detailed.

- The body must contain 4 separate paragraphs: a) Introduction and Objective, b) Methods, c) Results and d) Conclusions.
- It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is helpful to the reviewers.
- Indicate the major new findings of the study.
- Abstracts will adhere to the ICCS standardization on terminology published in *Journal of Urology*, 2014 191(6): 1863-1865 or *Neurourol Urodyn*. 2016 Apr;35(4): 471-81.
- Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
- Graphs and/or tables may be used; characters in graphs and tables are counted towards the overall character limit of the abstract.
- Proprietary names of drugs are not allowed; generic names must be used.

**6. Source of Funding:** Grant support must be indicated on the "Source of Funding" page. If there is no support, "None" must be listed. This is a required field in the submission process. Abstracts deemed to be purely for marketing purposes will not be accepted.

**7. Conflict of Interest and Disclosure Statement:** All authors must disclose conflicts of interest. The electronic submission process will not allow abstracts to be submitted without this information being completed for each author listed on the abstract.

**8. Category List:** Authors must select a category track and session from the provided list.